A weekly round-up of the
latest coverage in psychedelics.
Receive the free weekly digest straight to your inbox every week
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
April 27 – May 3, 2026
This week's feed, sponsored by
ICPR 2026 is Europe’s premier conference on psychedelic science and therapy, organised since 2010 by the OPEN Foundation. The seventh edition will take place on 4-6 June 2026, at PHIL in Haarlem, the Netherlands. Building on the success of previous years, ICPR 2026 will explore rigorous science, critical perspectives, and innovative psychedelic therapies. Use code PALPHA10 for 10% off.
More Info & TicketsA Note From the Editor
This week saw mainstream media’s flurry of psychedelics-related stories fizzle out as President Trump’s executive order (EO) slid down the news cycle. Insiders, meanwhile, continue to grapple with the implications of the EO, and how to best navigate next steps.
To that end, I spoke with Americans for Ibogaine CEO W. Bryan Hubbard for our latest Pα+ interview. We were both in Denver, Colorado, for the National Council for Mental Wellbeing’s annual meeting, where there were three psychedelics-related panels.
Speaking of gatherings, this week, the Interdisciplinary Conference on Psychedelic Research (ICPR) unveiled its full speaker lineup and agenda. I am excited to once again be attending this June conference, which takes place in Haarlem, near Amsterdam, alongside other members of the Psychedelic Alpha team. I’ll be giving one of the opening talks on Thursday morning and hope to see you there.
Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelic business, policy, research and beyond.
Josh Hardman
Founder & Editor
'Great potential': Psychedelic treatments gain traction as Texas expands research
Austin American-Statesman ↗
Pα+
An insider’s guide to the business,
policy and science of psychedelics.
Basic
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||